Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective
Authors:
- 1 January 2021
- journal article
- editorial
- Published by Elsevier in The Lancet Rheumatology
- Vol. 3 (1) , e71-e82
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Diagnosis of giant cell arteritis: when should we biopsy the temporal artery?British Journal of Oral and Maxillofacial Surgery, 2016
- Is temporal artery biopsy essential in all cases of suspected giant cell arteritis?2015
- Temporal artery biopsy: are we doing it right?International Journal of Health Care Quality Assurance, 2013
- Validity of the American College of Rheumatology Criteria for the Diagnosis of Giant Cell ArteritisAmerican Journal of Ophthalmology, 2012
- Influence of Previous Corticosteroid Therapy on Temporal Artery Biopsy Yield in Giant Cell ArteritisSeminars in Arthritis and Rheumatism, 2007
- Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta‐analysisArthritis & Rheumatism, 2007
- Temporal artery biopsy… Who needs one?Postgraduate Medical Journal, 2006
- How Does Previous Corticosteroid Treatment Affect the Biopsy Findings in Giant Cell (Temporal) Arteritis?Annals of Internal Medicine, 1994
- Clinical usefulness of temporal artery biopsy.Annals of the Rheumatic Diseases, 1987
- THE THERAPEUTIC IMPACT OF TEMPORAL ARTERY BIOPSYThe Lancet, 1983